According to the data, as of August 29, 342 A-share pharmaceutical companies disclosed the performance reports for the first half of 2022, of which 184 pharmaceutical companies achieved year-on-year growth in net profit attributable to the mother, accounting for 53.
8%.
From the perspective of segments, the performance of the CXO (pharmaceutical outsourcing services, including CDMO and CRO) segments rose
sharply.
Taking WuXi AppTec as an example, in the first half of this year, WuXi AppTec achieved revenue increased by 68.
52% year-on-year to 17.
756 billion yuan; net profit attributable to shareholders of listed companies increased by 73.
29% year-on-year to 4.
636 billion yuan; and non-net profit increased by 81% year-on-year to 3.
850 billion yuan
.
As for the reasons for the growth in performance, WuXi AppTec said that during the reporting period, the company continued to strengthen the unique integrated CRDMO (contract research, development and production) and CTDMO (contract testing, research and development and production) business models, giving full play to the advantages of global layout, multi-site operation and full industry chain coverage, timely formulation and efficient implementation of business continuity plans, to ensure the achievement
of the company's overall performance goals.
While maintaining the rapid growth of operating income, the efficiency of operation and management has been continuously improved
.
In addition to WuXi AppTec, the net profit attributable to the parent of CXO companies such as Boteng Shares, Gloria Ying, Baicheng Pharmaceutical, and Yaokang Biotech has increased by more than 50%
year-on-year.
Among them, the net profit attributable to Boteng shares and Gloria Ying increased by more than 300%
year-on-year.
Among them, the operating income of Boteng Co.
, Ltd.
in the first half of the year increased by 211.
67% year-on-year to 3.
914 billion yuan; the net profit attributable to the shareholders of the listed company increased by 465.
01% year-on-year to 1.
212 billion yuan; and the net profit attributable to the shareholders of the listed company after deducting non-recurring gains and losses increased by 501.
87% year-on-year to 1.
211 billion yuan
.
Boteng said that in the first half of 2022, thanks to the strong growth of the API CDMO business in the core business segment, the company achieved good semi-annual performance
.
The report also shows that among the three major business segments of Boteng Co.
, Ltd.
, the API CDMO business achieved an increase of 212% year-on-year in operating income to 3.
889 billion yuan; The preparation CDMO business achieved an increase of 154% year-on-year in operating income to 8.
9832 million yuan; The gene cell therapy CDMO business achieved an increase of 80% year-on-year in operating income to 11.
2671 million yuan
.
In the first half of this year, Gloria Ying achieved revenue of RMB5.
034 billion (the same unit below), an increase of 186.
7% year-on-year; Net profit attributable to shareholders of listed companies was 1.
74 billion yuan, an increase of 305.
3% year-on-year; The adjusted net profit attributable to shareholders of listed companies was 1.
537 billion yuan, an increase of 244.
8%
year-on-year.
The report shows that Gloria Ying's small molecule business achieved high-quality delivery of large orders in the first half of 2022, and established the industry demonstration effect with actual delivery capacity, continued to expand the number of projects and service pipelines, and effectively promoted the leapfrog growth of the company's small molecule CDMO business, and the small molecule CDMO business increased by 187.
6% year-on-year during the reporting period; During the reporting period, Gloria Ying also increased its efforts to carry out diversified, multi-regional and multi-stage market development, and the domestic market revenue increased by 264.
2% year-on-year; The company's emerging business includes preparations, chemical macromolecules, biosynthetic technology, biological macromolecules, clinical CRO and other sectors, in the first half of 2022 compared with the same period to achieve a revenue growth of 174.
2%, a number of sectors revenue growth of more than 200%, vigorously expand new customers and projects, for the company to provide new revenue growth points
.
In the first half of this year, Baicheng Pharmaceutical achieved an increase of 73.
91% year-on-year to 246 million yuan in operating income and a net profit of 107.
62% year-on-year to 85.
0213 million yuan
.
As for the reasons for the increase in operating income, Baicheng Pharmaceutical said that it was mainly due to the continuous expansion of the scale of business, and the company's post-marketing equity share income of 30.
9452 million yuan in the current period, which was a substantial increase over
the same period last year.
In the first half of this year, Yaokang Bio achieved revenue increased by 40.
29% year-on-year to 250 million yuan; Net profit attributable to the mother increased by 76.
16% year-on-year to 81.
64 million yuan; Net profit after deduction of non-net profit increased by 42.
2% year-on-year to RMB54.
42
million.
Yaokang Biology said that the growth of operating income in the first half of the year was mainly due to the sustained and rapid development of the company's business, of which the sales business of commercialized mouse models and the revenue of functional efficacy business increased by 46.
14% and 99.
96%
respectively year-on-year.
For the CXO industry performance soared, industry insiders said that since the beginning of this year, a number of policies have been introduced, and the attitude of supporting the rapid development of the innovative pharmaceutical and device industry is clear, pharmaceutical innovation is the main logic of the development of the entire industry, and CXO companies will benefit for
a long time.
Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.
